Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Traficet-EN (CCX282-B), an ora...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
Bibliographic Details
Main Authors:
Bekker, P
,
Velde, A
,
Pronk, I
,
Keshav, S
,
Hommes, D
,
Hanauer, S
,
Ungashe, S
,
Zheng, W
,
Wright, K
,
Schall, T
Format:
Conference item
Published:
2007
Holdings
Description
Similar Items
Staff View
Similar Items
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
by: Keshav, S, et al.
Published: (2007)
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
by: Bekker, P, et al.
Published: (2009)
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
by: Keshav, S, et al.
Published: (2009)
PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
by: Keshav, S, et al.
Published: (2007)
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
by: Bekker, P, et al.
Published: (2008)